v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 1,915 $ 1,309
General and administrative 1,631 1,421
Impairment of goodwill 2,044
Total operating expenses 5,590 2,730
Loss from operations (5,590) (2,730)
Other income (expense), net:    
Forward sales contract expense (5,335)
Change in fair value of warrant liabilities 1
Interest income, net 44 5
Other expense, net (135)
Total other income (expense), net 44 (5,464)
Loss before income taxes (5,546) (8,194)
Benefit (provision) for income taxes 40 (8)
Net loss $ (5,506) $ (8,202)
Net loss per common share - basic $ (6.95) $ (57.76)
Net loss per common share - diluted $ (6.95) $ (57.76)
Weighted average shares outstanding - basic 792 142
Weighted average shares outstanding - diluted 792 142